Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04469530 · ClinicalTrials.gov registry record · Phase 2
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
A Phase 2 study of Solid Tumor, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 5
- Study locations
NCT04469530 is a Phase 2 study of Solid Tumor that is actively recruiting participants, run by Emory University. The registered enrollment target is 55 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT04469530, a Phase 2 study of Solid Tumor, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, as compared to high-risk solid tumor patients treated with observation alone following completion of "standard" therapy.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Sirolimus
- DRUG Etoposide
- DRUG Celecoxib
Study Locations (5)
Georgia
- Aflac Cancer & Blood Disorders Centers - Atlanta
- Children's Healthcare of Atlanta - Atlanta
Missouri
- Washington University School of Medicine - St Louis
Pennsylvania
- Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC) - Pittsburgh
Texas
- Texas Children's Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2020-09-16 |
| Est. Completion | 2029-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04469530
The ClinicalTrials.gov registry entry for NCT04469530 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (75% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04469530 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Georgia, Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04469530 about?
NCT04469530 is a clinical study titled "Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors". The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, as...
What is the current status of trial NCT04469530?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2020-09-16. Estimated completion is 2029-02.
What conditions does trial NCT04469530 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT04469530?
The interventions under investigation include: Cyclophosphamide (DRUG), Sirolimus (DRUG), Etoposide (DRUG), Celecoxib (DRUG).
Who is sponsoring clinical trial NCT04469530?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04469530 being conducted?
This trial has 5 study locations across Georgia, Missouri, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
RECRUITING · Phase 2
-
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
RECRUITING · Phase 2
-
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.